Update on treatment of hereditary angioedema

Xu, Ying; Buyantseva, Larisa; Agarwal, Navneet; Olivieri, K.; Zhi, Yu; Craig, Timothy J.

doi:10.1111/cea.12080

Cited by 17 publications

(20 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The spectrum of angioedema, particularly the bradykinin associated forms, was reviewed in April by Busse and Buckland, and new developments in treatment were reviewed by Xu et al. . In addition, we reported a study by Saule et al.…”

Section: Clinical Allergymentioning

confidence: 94%

Developments in the field of allergy in 2013 through the eyes of Clinical and Experimental Allergy

Blankestijn

Boyle

Gore

et al. 2014

Clin Experimental Allergy

View full text Add to dashboard Cite

Summary 2013 was another exciting year for allergy in general and Clinical and Experimental Allergy in particular. In the field of asthma and rhinitis, there continued to be a focus on heterogeneity and phenotypes with increasing use of biostatistical techniques to determine clusters of similar populations. Obesity‐ and aspirin‐associated disease are intriguing associations with asthma which were explored in a number of papers. We published a number of excellent papers on mechanisms of airway inflammation and how this relates to physiology, pathology, genetics and biomarkers in both human and experimental model systems. In terms of mechanisms, there is less on individual cell types in allergic disease at the moment, but the immunology of allergic disease continued to fascinate our authors. Another area that was popular both in the mechanisms and in the epidemiology sections was early life events and how these lead to allergic disease, with an increasing focus on the role of the microbiome and how this influences immune tolerance. In the clinical allergy section, oral immunotherapy for food allergy is clearly a major topic of interest at the moment as was in vitro testing to distinguish between sensitization and allergic disease. There was less on inhalant allergy this year, but a good representation from the drug allergy community including some interesting work on non‐IgE‐mediated mechanisms. In the allergen section, important new allergens continue to be discovered, but the major focus as in the last couple of years was on working out how component‐resolved approaches can improve diagnosis and management of food and venom allergy.

show abstract

Section: Clinical Allergymentioning

confidence: 94%

Developments in the field of allergy in 2013 through the eyes of Clinical and Experimental Allergy

Blankestijn

Boyle

Gore

et al. 2014

Clin Experimental Allergy

View full text Add to dashboard Cite

show abstract

“…Plasma-derived C1-inh concentrates have been widely used for many years and carry the potential risk of contamination of pathogens as in the case with other plasma-derived products [37]. The recombinant human C1-inh was produced as an alternative and has been used to treat angioedema atacks for a few years in some countries.…”

Section: C1-inh Concentratesmentioning

confidence: 99%

Hereditary Angioedema

Gelincik¹,

Demir²

2017

A Comprehensive Review of Urticaria and Angioedema

View full text Add to dashboard Cite

Hereditary angioedema (HAE) is an autosomal dominantly inherited orphan disease manifested by recurrent unpredictable nonpiting and nonpruritic swelling atacks without urticarial plaques. HAE is caused by a deiciency of the C1 esterase inhibitor (C1-inh) or decreased function of C1-inh. Type 1 HAE, the most common form, occurs due to C1-inh deiciency and is seen with low-serum C1-inh levels. In type 2 HAE, the function of C1-inh is impaired, and in HAE with normal C1-inh serum levels, the function of C1-inh is normal. HAE episodes can afect various sites in the body such as the larynx, face, extremities, gastrointestinal tract, and urogenital area. Acute episodes can be treated with C1-inh concentrates, a kallikrein inhibitor, called ecallantide and bradykinin B2 receptor antagonist, icatibant. Depending on the frequency, severity, and location of the episodes, long-term prophylaxis regimens with plasma-derived C1-inh concentrates, antiibrinolytics, or 17α-alkylated androgens can be used. C1-inh concentrates or 17α-alkylated androgens should be administered before dental procedures and minor or major surgical interventions to provide short-term prophylaxis. In conclusion, HAE is a rare life-threatening disease of which clinical presentation is highly variable and early accurate diagnosis signiicantly prevents mortality and morbidity.

show abstract

“…[58][59][60] En otras partes del mundo existen otras opciones de tratamiento, algunas reemplazan la proteína deficiente, como el C1 inhibidor humano derivado del plasma y el C1 inhibidor recombinante; [61][62][63] así como el ecallantide, un inhibidor reversible de la calicreína plasmática. [64][65][66] La elección del tratamiento depende de la edad, frecuencia y gravedad de los ataques y la disponibilidad de los medicamentos.…”

Section: Tratamientounclassified

Angioedema

Holguín-Gómez

Vásquez-Ochoa

Cardona

2016

RAM

View full text Add to dashboard Cite

Angioedema is defined as edema of the skin or mucosa, including the respiratory and the gastrointestinal mucosa, which is self-limiting, and in most cases is completely resolved in less than 72 hours. It occurs due to increased permeability of the mucosal and submucosal capillaries and postcapillary venules, with resulting plasma extravasation. There are different types of angioedema: histaminergic (which may be mediated by immunoglobulin E), hereditary, from acquired C1 inhibitor deficiency, from angiotensin converting enzyme inhibitor, bradykinin-mediated, and nonhistaminergic idiopathic angioedema. Treatment depends on the cause of angioedema, age, and the frequency and severity of manifestations. The main measures are avoiding external triggers or causes, giving antihistamines, steroids, or adrenaline for histaminergic angioedema; replacing the deficient protein or blocking the action of bradykinin in C1 inhibitor deficiency and angioedema from angiotensin converting enzyme inhibitor.

show abstract

Update on treatment of hereditary angioedema

Cited by 17 publications

References 48 publications

Developments in the field of allergy in 2013 through the eyes of Clinical and Experimental Allergy

Developments in the field of allergy in 2013 through the eyes of Clinical and Experimental Allergy

Hereditary Angioedema

Angioedema

Contact Info

Product

Resources

About